Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
07/2010
07/01/2010US20100168141 Azetidine analogues nucleosidase and phosphorylase inhibitors
07/01/2010US20100168139 Inhibitors of human phosphatidylinositol 3-kinase delta
07/01/2010US20100168128 Small-molecule inhibitors of the androgen receptor
07/01/2010US20100168123 Akt protein kinase inhibitors
07/01/2010US20100168118 Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
07/01/2010US20100168117 A process for the preparation of the stable, amorphous calcium salt of (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid
07/01/2010US20100168107 Imidazole compounds for the treatment of neurodegenerative disorders
07/01/2010US20100168100 Quinoline derivatives as p13 kinase inhibitors
07/01/2010US20100168085 Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
07/01/2010US20100168077 Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof
07/01/2010US20100168073 Method for treating and/or preventing retinal diseases with sustained release corticosteroids
07/01/2010US20100168070 Compounds for the treatment of alzheimer's disease
07/01/2010US20100168065 Quinolinone derivatives as parp and tank inhibitors
07/01/2010US20100168064 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
07/01/2010US20100168062 Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors
07/01/2010US20100168060 Salts of benzimidazolyl pyridyl ethers and formulations thereof
07/01/2010US20100168052 Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
07/01/2010US20100168051 Altered Mitochondrial Activity in Diseases Resulting From Oxidative Stress
07/01/2010US20100168050 Compounds having antiangiogenic activity
07/01/2010US20100168039 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
07/01/2010US20100168038 Use of compounds in combination with gamma-irradiation for the treatment of cancer
07/01/2010US20100168036 Growth factor
07/01/2010US20100168035 Subcutaneous implants containing a degradation-resistant polylactide polymer
07/01/2010US20100168032 Smart Pro-Drugs of Serine Protease Inhibitors
07/01/2010US20100168029 Methods for treating bone tumors
07/01/2010US20100168028 Compositions and methods of using crmp-1 and its fragments for treating cancer
07/01/2010US20100168027 Bpc-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
07/01/2010US20100168019 Peptide conjugated anti-cancer prodrugs
07/01/2010US20100168012 Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture
07/01/2010US20100168002 Therapeutic peptides
07/01/2010US20100167999 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
07/01/2010US20100167994 Targeting of ews-fli1 as anti-tumor therapy
07/01/2010US20100167393 Modified human thymic stromal lymphopoietin
07/01/2010US20100167377 Recombinant viruses comprising the membrane-proximal domain of VSV G protein
07/01/2010US20100166895 Capsicum extract for treatment of skin cancer
07/01/2010US20100166892 Herbal composition phy906 and its use in chemotherapy
07/01/2010US20100166884 Potentiation of cancer chemotherapy by 7-(2, 5- dihydro- 4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine
07/01/2010US20100166882 Composition comprising egg white-chalcanthite for preventing or treating cancer
07/01/2010US20100166881 Novel IDO Inhibitors and Methods of Use Thereof
07/01/2010US20100166876 Loading of hydrophobic drugs into hydrophilic polymer delivery systems
07/01/2010US20100166874 Technology for Preparation of Macromolecular Microspheres
07/01/2010US20100166872 Novel improved compositions for cancer therapy
07/01/2010US20100166865 Nanoparticle compositions
07/01/2010US20100166848 Liposomal formulations for treating cancer
07/01/2010US20100166845 Individualized cancer therapy
07/01/2010US20100166843 Pharmaceutical composition comprising a campothecin derivative
07/01/2010US20100166840 Liposome having lipid membrane containing bacterial cell component
07/01/2010US20100166838 Methods And Compositions For Modulating Keratinocyte Function
07/01/2010US20100166819 Transforming Growth Factor Modulators
07/01/2010US20100166799 Adenoviral vectors and methods and uses related thereto
07/01/2010US20100166797 Gammaretrovirus associated with cancer
07/01/2010US20100166790 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
07/01/2010US20100166785 lipopeptide or lipoprotein that is not only highly immunogenic itself but also can enhance the immunogenicity of other antigens; vaccine
07/01/2010US20100166782 Clip inhibitors and methods of modulating immune function
07/01/2010US20100166781 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
07/01/2010US20100166779 Monoclonal Antibodies Against Claudin-18 for Treatment of Cancer
07/01/2010US20100166777 Hematopoietic cells that express mosc-1
07/01/2010US20100166776 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
07/01/2010US20100166775 S100a9 interaction screening method
07/01/2010US20100166755 Anti-egfr antibodies
07/01/2010US20100166751 Cancer therapy using whole glucan particles and antibodies
07/01/2010US20100166749 Polypeptide variants with altered effector function
07/01/2010US20100166747 Methods and compositions for treating tumor diseases
07/01/2010US20100166746 High potency recombinant antibodies, methods for producing them and use in cancer therapy
07/01/2010US20100166745 Transferrin receptor antibodies
07/01/2010US20100166744 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
07/01/2010US20100166741 Altered br-3 binding polypeptides
07/01/2010US20100166737 P38Alpha as a Therapeutic Target in Bladder Carcinoma
07/01/2010US20100166731 Methods and Compositions for Treating Cancer
07/01/2010US20100166727 S-Adenosylmethionine And Methylthioadensosine In Chemoprevention And Treatment Of Colon Polyps And Cancer
07/01/2010US20100166724 Uses of thioredoxin
07/01/2010US20100166722 T cell therapies
07/01/2010US20100166707 Extracellular matrix/metastasis modifier genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
07/01/2010US20100166699 Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
07/01/2010US20100166697 Combination therapy using tnf and alfa-galactosyl ceramide
07/01/2010US20100166670 Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity
07/01/2010US20100166654 Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery
07/01/2010US20100166652 Laminin receptor 1 precursor protein (37LRP) epitope delineated by an hepatocellular carcinoma specific antibody
07/01/2010US20100166651 Radiotherapeutic High Specific Activity Tin-117m and Methods of Use
07/01/2010US20100166649 Method to inhibit cancer targeting cd24
07/01/2010DE102008063667A1 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
07/01/2010DE102008062826A1 Pyridazinonderivate Pyridazinone derivatives
07/01/2010DE102006024834B4 Neue Indol-Pyrrol-Derivate und deren Verwendungen New indole-pyrrole derivatives and their uses
07/01/2010CA2750841A1 Pyrimidine indole derivatives for treating cancer
07/01/2010CA2748990A1 Diagnosis and treatment of cancer using anti-lgr7 antibody
07/01/2010CA2748397A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use
07/01/2010CA2748339A1 Plant extracts from acronychia species and their use
07/01/2010CA2748289A1 Preparation method of dihydroindene amide compounds,their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
07/01/2010CA2748250A1 Indanyl compounds
07/01/2010CA2748249A1 Cyclic amine compounds
07/01/2010CA2748218A1 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
07/01/2010CA2748161A1 Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
07/01/2010CA2748158A1 Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
07/01/2010CA2748124A1 Ppar agonist compositions and methods of use
07/01/2010CA2747938A1 Immunostimulating saponins for use in in situ tumor-destruction therapy
07/01/2010CA2747932A1 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives
07/01/2010CA2747863A1 Pyridazinone derivatives
07/01/2010CA2747811A1 Coumarin-based compounds
07/01/2010CA2747805A1 Methods for treating or preventing cancer and neurodegenerative diseases
07/01/2010CA2747686A1 C1orf59 peptides and vaccines including the same
1 ... 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 ... 2211